These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15755287)

  • 21. Utility of FDG PET/CT in guiding antifungal therapy in acute leukemia patients with chronic disseminated candidiasis.
    Xu B; Shi P; Wu H; Guo X; Wang Q; Zhou S
    Clin Nucl Med; 2010 Aug; 35(8):567-70. PubMed ID: 20631500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoimmune lymphoproliferative syndrome and non-Hodgkin lymphoma: what 18F-fluorodeoxyglucose positron emission tomography/computed tomography can do in the management of these patients? Suggestions from a case report.
    Cistaro A; Pazè F; Durando S; Cogoni M; Faletti R; Vesco S; Vallero S; Quartuccio N; Treglia G; Ramenghi U
    Rev Esp Med Nucl Imagen Mol; 2014; 33(2):99-102. PubMed ID: 23845452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of advanced non-Hodgkin's lymphoma involving the prostate: staging and treatment monitoring using F-18 FDG PET/CT imaging.
    Cimarelli S; Lachenal F; Ricard F; Chassagne-Clément C; Heudel PE; Janody P; Sebban C
    Clin Nucl Med; 2010 Jun; 35(6):425-7. PubMed ID: 20479591
    [No Abstract]   [Full Text] [Related]  

  • 24. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.
    Svoboda J; Andreadis C; Elstrom R; Chong EA; Downs LH; Berkowitz A; Luger SM; Porter DL; Nasta S; Tsai D; Loren AW; Siegel DL; Glatstein E; Alavi A; Stadtmauer EA; Schuster SJ
    Bone Marrow Transplant; 2006 Aug; 38(3):211-6. PubMed ID: 16770314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.
    Leemhuis T; Wells S; Scheffold C; Edinger M; Negrin RS
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):181-7. PubMed ID: 15744236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
    Kostakoglu L; Evens AM
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):20-35. PubMed ID: 25000313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients.
    Bouard L; Bodet-Milin C; Bailly C; Guillaume T; Peterlin P; Garnier A; Bourgeois AL; Mahé B; Dubruille V; Blin N; Touzeau C; Gastinne T; Lok A; Bonnet A; Béné MC; Gouill SL; Moreau P; Kraeber-Bodéré F; Chevallier P
    Biol Blood Marrow Transplant; 2019 May; 25(5):906-911. PubMed ID: 30481598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants.
    Slavin S; Nagler A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S59-67. PubMed ID: 9457396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma.
    Ulaner GA; Goldman DA; Sauter CS; Migliacci J; Lilienstein J; Gönen M; Schöder H; Moskowitz CH; Zelenetz AD
    Radiology; 2015 Nov; 277(2):518-26. PubMed ID: 26035588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma.
    Muslimani AA; Farag HL; Francis S; Spiro TP; Chaudhry AA; Chan VC; Taylor HC; Daw HA
    Am J Clin Oncol; 2008 Oct; 31(5):409-12. PubMed ID: 18838874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.
    Bachanova V; Burns LJ; Ahn KW; Laport GG; Akpek G; Kharfan-Dabaja MA; Nishihori T; Agura E; Armand P; Jaglowski SM; Cairo MS; Cashen AF; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Ghosh N; Holmberg LA; Inwards DJ; Kanate AS; Lazarus HM; Malone AK; Munker R; Mussetti A; Norkin M; Prestidge TD; Rowe JM; Satwani P; Siddiqi T; Stiff PJ; William BM; Wirk B; Maloney DG; Smith SM; Sureda AM; Carreras J; Hamadani M;
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1605-11. PubMed ID: 25983043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of residual Hodgkin's disease demonstrated by PET/CT in a deceased organ donor.
    Prior JO; Duchosal MA; Schmidt S; Turini P; Pilon N; Chioléro R; Pascual M
    Transpl Int; 2010 Jan; 23(1):101-4. PubMed ID: 19682299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
    Spaepen K; Mortelmans L
    Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of 18F-FDG-PET in the diagnosis of endoprosthetic loosening of knee and hip implants.
    Mayer-Wagner S; Mayer W; Maegerlein S; Linke R; Jansson V; Müller PE
    Arch Orthop Trauma Surg; 2010 Oct; 130(10):1231-8. PubMed ID: 19890653
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of
    McDonald EO; Amanullah AA; Park PSU; Song W; Werner TJ; Alavi A; Revheim ME
    Ann Nucl Med; 2023 Jun; 37(6):328-348. PubMed ID: 37095393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation?
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Nucl Med Commun; 2016 Jan; 37(1):23-9. PubMed ID: 26440567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
    Araf S; Montoto S
    Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dealing with bone marrow biopsies in the staging of classical Hodgkin lymphoma: an old issue revisited in the (18)F-fluorodeoxyglucose-positron emission tomography era.
    Gonçalves Mde C; de Paula HM; Linardi Cda C; Cerci JJ; Aldred VL; Siqueira SA; Buccheri V; Zerbini MC
    Leuk Lymphoma; 2015; 56(10):2883-8. PubMed ID: 25697914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.
    Sioka C
    Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.